Zimmer Biomet, a major maker of orthopedic devices, reported another solid quarter and raised its profit outlook for the year, signaling that its ongoing overhaul of US sales operations is beginning to bear fruit.
The company said second-quarter revenue rose 4.8% from a year earlier to $2.18 billion, beating analysts' average estimate of $2.13 billion. Adjusted earnings came in at $2.07 per share, ahead of the $2.01 expected by Wall Street.
Looking ahead, Zimmer Biomet lifted its adjusted earnings forecast for the full year to a range of $8.47 to $8.59 per share, up from its previous guidance. The move reflects management's confidence that the momentum from the first half will continue.
US sales model shift drives growth
The company has been transitioning to a more specialized US sales model, where sales representatives focus on specific product lines rather than selling the entire portfolio. This strategy aims to deepen expertise and improve customer relationships, but it has taken time to implement and has been a key focus for investors.
The US, which accounted for about 58% of net sales in 2025, again led the way. Sales in the region grew 5.6% to $1.24 billion in the quarter ended June 30. By product category, hips rose 5% to $562.7 million, while knees were essentially flat at $828.9 million. Sports medicine and other segments also contributed to the overall growth.
The strong US performance suggests the new model is gaining traction, even as the company works through the transition. Analysts have been watching closely to see whether the shift would disrupt sales or eventually boost them; so far, the results point to the latter.
What this means for investors
For everyday investors, Zimmer Biomet's raised outlook is a positive signal that the company's strategic changes are translating into better financial performance. Beating estimates and lifting guidance often indicate that management sees continued strength ahead.
However, it's important to note that the company's growth is not uniform across all product lines. Knees, a major segment, were flat, which could be a point of concern if that trend persists. Still, the overall revenue growth and earnings beat suggest the company is on a solid footing.
Investors should also consider the broader context. The orthopedic-device industry faces ongoing pricing pressures and competition, but demand for joint replacements and sports medicine procedures tends to be resilient, driven by an aging population and active lifestyles.
Zimmer Biomet's performance is part of a broader earnings season where several companies have raised their outlooks. For instance, Schneider Electric lifted its outlook on strong data center demand, and Honda raised its profit forecast thanks to a weaker yen. These moves reflect a generally healthy corporate earnings environment, though each company's story is unique.
For those holding Zimmer Biomet shares, the raised guidance is a welcome development. But as always, it's wise to keep an eye on how the US sales transition progresses and whether the company can maintain its growth trajectory in the coming quarters.
The company's next earnings report will be closely watched to see if the momentum continues and whether the full-year forecast proves conservative or optimistic.
